Nascent Biotech, Inc. (NBIO)
| Market Cap | 16.96M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.09M |
| Shares Out | 169.73M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,700 |
| Open | 0.0999 |
| Previous Close | 0.0853 |
| Day's Range | 0.0999 - 0.0999 |
| 52-Week Range | 0.0323 - 0.2800 |
| Beta | -3.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NBIO
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Th... [Read more]
Financial Performance
Financial StatementsNews
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal a...
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal a...
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the develop...
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a ...
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the devel...
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the develop...
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focu...
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / June 7, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused...
Nascent Biotech Regains Worldwide Rights for Pritumumab
NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused...
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused ...
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focus...
Nascent Announces the Completion of Its Phase1 Clinical Trials
NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is fo...
Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal...
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the develo...
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal anti...
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company who develops monoclonal ant...
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company focused on the development o...
Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the developmen...
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
VERO BEACH, FL / ACCESSWIRE / July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of ...
Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of m...
Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc ...
The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial
SAN DIEGO, CA / ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational immunother...
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal VERO BEACH, FL / ACCESSWIRE / February 23, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Com...
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development ...